Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 5 Total length of hospital stay in the pooled analysis (mITT population)

From: Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials

 

Rezafungin

(N = 139)

Caspofungin

(N = 155)

Absolute difference

Relative difference c

All patients

Hospital LoS unadjusted mean (SD)a, days

25.2 (19.26)

28.3 (20.16)

3.1

1.12 (95% CI 0.94,1.33)

Hospital LoS adjusted mean (95% CI)a, days

25.9 (22.2,28.6)

28.8 (25.2,31.9)

2.9

1.11 (0.94,1.33)

Survivors onlyb

n (%)

112 (80.6)

125 (80.6)

–

–

Hospital LoS unadjusted mean (SD), days

25.7 (18.4)

28.7 (17.9)

3.0

–

Back to article page

Critical Care

ISSN: 1364-8535